TABLE OF CONTENTS
1 INTRODUCTION 42
1.1 OBJECTIVES OF THE STUDY 42
1.2 MARKET DEFINITION 42
1.3 OVERVIEW OF THE EUROPE CONTRACT MANUFACTURING MARKET 42
1.4 CURRENCY AND PRICING 44
1.5 LIMITATIONS 44
1.6 MARKETS COVERED 44
2 MARKET SEGMENTATION 47
2.1 MARKETS COVERED 47
2.2 GEOGRAPHICAL SCOPE 48
2.3 YEARS CONSIDERED FOR THE STUDY 49
2.4 DBMR TRIPOD DATA VALIDATION MODEL 50
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 53
2.6 MULTIVARIATE MODELLING 54
2.7 PRODUCT SEGMENT LIFELINE CURVE 54
2.8 MARKET END USER COVERAGE GRID 55
2.9 DBMR MARKET POSITION GRID 56
2.10 VENDOR SHARE ANALYSIS 57
2.11 SECONDARY SOURCES 58
2.12 ASSUMPTIONS 58
3 EXECUTIVE SUMMARY 59
4 PREMIUM INSIGHTS 61
4.1 PESTEL ANALYSIS 62
4.2 PORTER'S FIVE FORCES 63
4.3 STRATEGIC INITIATIVES: 64
5 REGULATORY FRAMEWORK 65
5.1 REGULATORY SCENARIO BY FDA 65
5.2 REGULATORY SCENARIO IN AUSTRALIA 66
5.3 REGULATORY SCENARIO IN EUROPE FOR MEDICINES 67
6 MARKET OVERVIEW 68
6.1 DRIVERS 70
6.1.1 COST-EFFECTIVENESS FOR THE MANUFACTURING COMPANIES 70
6.1.2 RISE OF TECHNOLOGICAL ADVANCEMENTS IN CONTRACT MANUFACTURING 70
6.1.3 EUROPE PRESENCE AND CONNECTED NETWORK 71
6.2 RESTRAINTS 71
6.2.1 STRINGENT REGULATIONS AMONG VARIOUS JURISDICTIONS 71
6.2.2 RISK OF CONFIDENTIAL INFORMATION 72
6.3 OPPORTUNITIES 72
6.3.1 PATENT EXPIRY AND INCREASING DEMAND FOR GENERIC DRUGS 72
6.3.2 GROWING EXPENSES ON THE DEVELOPMENT OF HEALTHCARE INFRASTRUCTURE 73
6.3.3 INCREASE IN NUMBER OF STRATEGIC INITIATIVES BY KEY MARKET PLAYERS 73
6.4 CHALLENGES 74
6.4.1 INTELLECTUAL PROPERTY RISKS 74
6.4.2 INCREASE IN NUMBER OF PHARMACEUTICAL COMPANIES TO SET UP THEIR MANUFACTURING SITES 74
7 EUROPE CONTRACT MANUFACTURING MARKET, BY PRODUCT 75
7.1 OVERVIEW 76
7.2 PHARMACEUTICAL PRODUCTS MANUFACTURING 79
7.2.1 TYPES OF PRODUCTS 80
7.2.1.1 TABLETS 80
7.2.1.2 CAPSULES 80
7.2.1.3 BIOLOGICS 81
7.2.1.4 SMALL MOLECULE 81
7.2.1.5 CELL & GENES MANUFACTURING 81
7.2.1.6 NUTRACEUTICALS 81
7.2.1.7 OTHERS 81
7.2.2 TYPE OF SERVICES 81
7.2.2.1 DRUG DEVELOPMENT SERVICES 82
7.2.2.2 TABLET MANUFACTURING SERVICES 82
7.2.2.3 BIOLOGICS API MANUFACTURING 82
7.2.2.4 BIOLOGICS FDF MANUFACTURING SERVICES 82
7.2.2.5 OTHERS 82
7.2.3 BY DOSAGE FORM 82
7.2.3.1 SOLID FORMULATIONS 83
7.2.3.2 LIQUID FORMULATIONS 83
7.2.3.2.1 INJECTABLE 83
7.2.3.2.2 SYRUPS 83
7.2.3.3 SEMI-SOLID FORMULATIONS 83
7.2.3.4 TOPICAL DRUG FORMULATIONS 83
7.2.3.5 OTHERS 83
7.3 MEDICAL DEVICE MANUFACTURING 84
7.3.1 TYPE OF DEVICES 85
7.3.1.1 SYRINGES AND NEEDLES 86
7.3.1.2 INFUSION DEVICES & ADMINISTRATION SETS 86
7.3.1.3 MEDICAL ACCESSORIES, COMPONENTS & CONSUMABLES 86
7.3.1.4 DISPOSABLES 86
7.3.1.5 IVD DEVICES 87
7.3.1.6 CARDIOVASCULAR DEVICES 87
7.3.1.7 DIABETES CARE DEVICES 87
7.3.1.8 GENERAL SURGERY DEVICES 87
7.3.1.9 ORTHOPEDIC DEVICES 87
7.3.1.10 RESPIRATORY DEVICES 87
7.3.1.11 OPHTHALMIC DEVICES 87
7.3.1.12 DENTAL DEVICES 87
7.3.1.13 GYNECOLOGY/UROLOGY DEVICES 87
7.3.1.14 LABORATORY EQUIPMENT 87
7.3.2 TYPE OF SERVICES 88
7.3.2.1 MEDICAL DEVICE DESIGN AND DEVELOPMENT 88
7.3.2.2 DEVICE ASSEMBLY 88
7.3.2.3 REGULATORY ASSISTANCE 88
7.3.2.4 PACKAGING & LABELLING 88
7.3.2.5 STERILIZATION SERVICES 89
7.3.2.6 TRAINING AND VALIDATION 89
7.3.2.7 QUALITY ASSURANCE 89
7.3.2.8 OTHERS 89
7.3.3 BY DEVICE CLASS 89
7.3.3.1 CLASS I MEDICAL DEVICES 90
7.3.3.2 CLASS IIA MEDICAL DEVICES 90
7.3.3.3 CLASS IIB MEDICAL DEVICES 90
7.3.3.4 CLASS III MEDICAL DEVICES 90
8 EUROPE CONTRACT MANUFACTURING MARKET, BY END USER 91
8.1 OVERVIEW 92
8.2 PHARMACEUTICAL COMPANIES 95
8.3 BIOTECHNOLOGY COMPANIES 95
8.4 BIOPHARMA COMPANIES 96
8.5 MEDICAL DEVICES COMPANIES 97
8.6 ORIGINAL EQUIPMENT MANUFACTURER 97
8.7 RESEARCH INSTITUTES 98
9 EUROPE CONTRACT MANUFACTURING MARKET, BY DISTRIBUTION CHANNEL 99
9.1 OVERVIEW 100
9.2 RETAIL SALES 103
9.3 DIRECT TENDER 104
9.4 OTHERS 105
10 EUROPE CONTRACT MANUFACTURING MARKET, BY REGION 106
10.1 EUROPE 107
10.1.1 GERMANY 120
10.1.2 FRANCE 128
10.1.3 U.K. 136
10.1.4 ITALY 144
10.1.5 SPAIN 152
10.1.6 RUSSIA 160
10.1.7 TURKEY 168
10.1.8 BELGIUM 176
10.1.9 NETHERLANDS 184
10.1.10 SWITZERLAND 192
10.1.11 REST OF EUROPE 200
11 EUROPE CONTRACT MANUFACTURING MARKET: COMPANY LANDSCAPE 201
11.1 COMPANY SHARE ANALYSIS: EUROPE 201
12 SWOT ANALYSIS 202
13 COMPANY PROFILE 203
13.1 AENOVA GROUP 203
13.1.1 COMPANY SNAPSHOT 203
13.1.2 COMPANY SHARE ANALYSIS 203
13.1.3 PRODUCT PORTFOLIO 204
13.1.4 RECENT DEVELOPMENTS 204
13.2 THERMO FISHER SCIENTIFIC INC. 205
13.2.1 COMPANY SNAPSHOT 205
13.2.2 REVENUE ANALYSIS 206
13.2.3 COMPANY SHARE ANALYSIS 206
13.2.4 PRODUCT PORTFOLIO 207
13.2.5 RECENT DEVELOPMENTS 207
13.3 EVONIK INDUSTRIES AG 208
13.3.1 COMPANY SNAPSHOT 208
13.3.2 REVENUE ANALYSIS 208
13.3.3 COMPANY SHARE ANALYSIS 209
13.3.4 PRODUCT PORTFOLIO 209
13.3.5 RECENT DEVELOPMENTS 209
13.4 LONZA 210
13.4.1 COMPANY SNAPSHOT 210
13.4.2 REVENUE ANALYSIS 210
13.4.3 COMPANY SHARE ANALYSIS 211
13.4.4 PRODUCT PORTFOLIO 211
13.4.5 RECENT DEVELOPMENTS 212
13.5 BOEHRINGER INGELHEIM INTERNATIONAL GMBH. 213
13.5.1 COMPANY SNAPSHOT 213
13.5.2 REVENUE ANALYSIS 213
13.5.3 COMPANY SHARE ANALYSIS 214
13.5.4 PRODUCT PORTFOLIO 214
13.5.5 RECENT DEVELOPMENTS 214
13.6 ABBVIE INC. 215
13.6.1 COMPANY SNAPSHOT 215
13.6.2 REVENUE ANALYSIS 215
13.6.3 PRODUCT PORTFOLIO 216
13.6.4 RECENT DEVELOPMENT 216
13.7 ALMAC GROUP 217
13.7.1 COMPANY SNAPSHOT 217
13.7.2 PRODUCT PORTFOLIO 217
13.7.3 RECENT DEVELOPMENTS 217
13.8 AVID BIOSERVICES, INC. 218
13.8.1 COMPANY SNAPSHOT 218
13.8.2 REVENUE ANALYSIS 218
13.8.3 PRODUCT PORTFOLIO 219
13.8.4 RECENT DEVELOPMENT 219
13.9 BAXTER 220
13.9.1 COMPANY SNAPSHOT 220
13.9.2 REVENUE ANALYSIS 220
13.9.3 PRODUCT PORTFOLIO 221
13.9.4 RECENT DEVELOPMENTS 222
13.10 CATALENT, INC 223
13.10.1 COMPANY SNAPSHOT 223
13.10.2 REVENUE ANALYSIS 223
13.10.3 PRODUCT PORTFOLIO 224
13.10.4 RECENT DEVELOPMENT 224
13.11 FAMAR HEALTH CARE SERVICES 225
13.11.1 COMPANY SNAPSHOT 225
13.11.2 PRODUCT PORTFOLIO 225
13.11.3 RECENT DEVELOPMENTS 225
13.12 JUBILANT PHARMA LIMITED 226
13.12.1 COMPANY SNAPSHOT 226
13.12.2 REVENUE ANALYSIS 226
13.12.3 PRODUCT PORTFOLIO 227
13.12.4 RECENT DEVELOPMENT 227
13.13 KIMBALL INTERNATIONAL 228
13.13.1 COMPANY SNAPSHOT 228
13.13.2 REVENUE ANALYSIS 228
13.13.3 PRODUCT PORTFOLIO 229
13.13.4 RECENT DEVELOPMENT 229
13.14 MERCK KGAA 230
13.14.1 COMPANY SNAPSHOT 230
13.14.2 REVENUE ANALYSIS 230
13.14.3 PRODUCT PORTFOLIO 231
13.14.4 RECENT DEVELOPMENTS 231
13.15 NIPR0 232
13.15.1 COMPANY SNAPSHOT 232
13.15.2 REVENUE ANALYSIS 232
13.15.3 PRODUCT PORTFOLIO 233
13.15.4 RECENT DEVELOPMENT 233
13.16 PFIZER INC 234
13.16.1 COMPANY SNAPSHOT 234
13.16.2 REVENUE ANALYSIS 234
13.16.3 PRODUCT PORTFOLIO 235
13.16.4 RECENT DEVELOPMENT 235
13.17 RECIPHARM AB. 236
13.17.1 COMPANY SNAPSHOT 236
13.17.2 REVENUE ANALYSIS 236
13.17.3 PRODUCT PORTFOLIO 237
13.17.4 RECENT DEVELOPMENT 237
13.18 SIEGFRIED HOLDING AG 238
13.18.1 COMPANY SNAPSHOT 238
13.18.2 REVENUE ANALYSIS 238
13.18.3 PRODUCT PORTFOLIO 239
13.18.4 RECENT DEVELOPMENTS 239
13.19 SUN PHARMACEUTICAL INDUSTRIES LTD 240
13.19.1 COMPANY SNAPSHOT 240
13.19.2 REVENUE ANALYSIS 240
13.19.3 PRODUCT PORTFOLIO 241
13.19.4 RECENT DEVELOPMENT 241
13.20 TE CONNECTIVITY 242
13.20.1 COMPANY SNAPSHOT 242
13.20.2 REVENUE ANALYSIS 242
13.20.3 PRODUCT PORTFOLIO 243
13.20.4 RECENT DEVELOPMENT 243
13.21 VETTER PHARMA-FERTIGUNG GMBH & CO. KG 244
13.21.1 COMPANY SNAPSHOT 244
13.21.2 PRODUCT PORTFOLIO 244
13.21.3 RECENT DEVELOPMENTS 244
14 QUESTIONNAIRE 245
15 RELATED REPORTS 248

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.